Vanguard Capital Management’s Calidi Biotherapeutics CLDI Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$1.71K Buy
1,595
+1
+0.1% +$2 ﹤0.01% 4059
2026
Q2
$4.34K Hold
1,594
– – ﹤0.01% 4070
2026
Q1
$6.1K Buy
+1,594
New +$19.2K ﹤0.01% 4033

Other funds holding CLDI

Vanguard Capital Management's CLDI Position: Q3 2026 in Review

Vanguard Capital Management increased its Calidi Biotherapeutics (CLDI) stake by 0.06% in Q3 2026, buying an estimated $2 and bringing the position to 1,595 shares worth $1.71K. The position accounts for ﹤0.01% of the portfolio, ranked #4059.

Vanguard Capital Management first reported a position in CLDI in Q1 2026 and has held it in 3 quarters since. The position peaked at $6.1K in Q1 2026. 20 funds tracked by Wall St. Rank hold CLDI as of Q3 2026.

  • Vanguard Capital Management held 1,595 shares of Calidi Biotherapeutics worth $1.71K as of Q3 2026.
  • Vanguard Capital Management bought 1 Calidi Biotherapeutics share in Q3 2026, an estimated $2.
  • Calidi Biotherapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #4059 holding.
  • Vanguard Capital Management first reported a position in Calidi Biotherapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Calidi Biotherapeutics position peaked at $6.1K in Q1 2026.
  • 20 funds tracked by Wall St. Rank held Calidi Biotherapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.